/Medtronic%20Plc%20logo-by%20360b%20via%20Shutterstock.jpg)
Galway, Ireland-based Medtronic plc (MDT) develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients. Valued at $116.2 billion by market cap, the company's principal products include those for bradycardia pacing, tachyarrhythmia management, atrial fibrillation management, heart failure management, heart valve replacement, malignant and non-malignant pain, and movement disorders. The global leader in medical technology is expected to announce its fiscal second-quarter earnings for 2025 on Tuesday, Nov. 19.
Ahead of the event, analysts expect MDT to report a profit of $1.24 per share on a diluted basis, down marginally from $1.25 per share in the year-ago quarter. The company has consistently surpassed Wall Street’s EPS estimates in its last four quarterly reports.
For the full year, analysts expect MDT to report EPS of $5.44, up 4.6% from $5.20 in fiscal 2024. Its EPS is expected to rise 7.2% year over year to $5.83 in fiscal 2026.
MDT stock has underperformed the S&P 500’s ($SPX) 41.4% gains over the past 52 weeks, with shares up 30.5% during this period. However, it outperformed the Health Care Select Sector SPDR Fund’s (XLV) 20.9% gains over the same time frame.
On Aug. 20, MDT shares closed up marginally after reporting its Q1 results. Its net sales stood at $7.9 billion, up 2.8% year over year. Its adjusted EPS of $1.23 grew 2.5% in the year-ago quarter. The company raised its adjusted EPS guidance to the range of $5.42 to $5.50.
Analysts’ consensus opinion on MDT stock is reasonably bullish, with a “Moderate Buy” rating overall. Out of 29 analysts covering the stock, 10 advise a “Strong Buy” rating, two suggest a “Moderate Buy” rating, 15 give a “Hold” rating, and two recommend a “Strong Sell.” MDT’s average analyst price target is $94.75, indicating a potential upside of 4.6% from the current levels.
On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
